Alisertib (MLN8237)

Catalog No.S1133

Alisertib (MLN8237) Chemical Structure

Molecular Weight(MW): 518.92

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 48 Publications

12 Customer Reviews

  • Inhibition of Aurka kinase activity by MLN8237 impairs expression of pluripotency genes in CCE cells as measured by qRT-PCR. All values shown are mean ?SEM for n=3. The level of phosphorylated H3(S10) (p-H3(S10)), an Aurka phosphorylation target site, is decreased in MLN8237-treated samples.

    Cell Stem Cell 2012 11, 179-94. Alisertib (MLN8237) purchased from Selleck.

    Recruitment of clathrin to the mitotic spindle is controlled by phosphorylation of TACC3 by Aurora-A kinase. Representative micrographs of HEK293 cells incubated with 0.3 μM MLN8237 for 40 min. Cells were fixed and stained as indicated.

    EMBO J 2012 30, 906-19. Alisertib (MLN8237) purchased from Selleck.

  • Tissue levels of 53BP1, a-tubulin, IkB-a and IL-6 in an Hs294T xenograft treated with MLN8237 or vehicle control were visualized by immunofluorescence co-staining with DAPI. Representative micrographs are shown from triplicate experiments.

    EMBO Mol Med 2013 5(1), 149-66. Alisertib (MLN8237) purchased from Selleck.

    NUSAP mitotic phosphorylation at Ser 240 correlates with Aurora A activity. Protein samples of FLAG-NUSAP immunoprecipitated from I, M and MtMLN or with MtZM were analysed using LC-MS/MS, focusing on the predicted phosphorylated residue Ser 240. The histograms (A, B) show the calculated ratios based on peptides carrying the phosphorylated Ser 240 compared with all matched peptides containing this residue.

     

     

    EMBO reports 2010 11, 977-984. Alisertib (MLN8237) purchased from Selleck.

  • Aurora A inhibition rescues the PPP6C depletion phenotype. (A) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 or 20 nM MLN8237 or a solvent control for 15 min before lysis in phosphatase inhibitor containing buffer or fixation. Total lysates were analyzed by Western blotting. The red and black lines indicate the hosphorylated and nonphosphorylated forms of Aurora A. Fixed cells were stained using DAPI to detect DNA and antibodies to α-tubulin and Aurora A pT288. The intensity of pT288 staining was integrated using ImageJ over the spindle region defined by TPX2 staining and is plotted in the bar graph ( n = 4). Arrowheads indicate micronuclei. Bar, 5 µm. (B) HeLa cells transfected for 48 h with control and PPP6C si08 duplexes were treated with 10 nM MLN8237 or a solvent control for 24 h before fixation and staining with DAPI to detect DNA.

    J Cell Biol 2010 191, 1315-32. Alisertib (MLN8237) purchased from Selleck.

    D) Pharmacological inhibition of AURKA using alisertib led to downregulation of p-EIF4E (S209) and c-MYC proteins in FLO-1 and SK-GT-4 resistant cells, with or without RAD001 treatment.

    Clin Cancer Res, 2017, 23(14):3756-3768. Alisertib (MLN8237) purchased from Selleck.

  • Eg5 inhibition counteracts the induction of spindle pole fragmentation by Aurora-A inactivation. The protocol to inhibit Aurora-A by MLN8237 in cells progressing towards mitosis is depicted (time intervals not represented to scale). Control cultures were treated with solvent (DMSO) in the same time window. When indicated, MON was added 1 hour before harvesting. Note the absence of active phosphorylated (pThr288) Aurora-A (in red in IF panels) in cells treated with MLN8237. Upper histograms represent the percentage of all spindle and MT abnormalities in control and MLN8237-treated cultures (200 counted PM/M per condition in 2 experiments); the grey fraction of the histograms represents mitoses with spindle extrapoles, while other defects (monopolar or disorganised spindles, few and short MTs) are in white. Lower histograms and IF panels show that concomitant Eg5 inhibition by MON prevents MLN8237-induced spindle pole fragmentation (note the failure of centrosome migration reflecting Eg5 inactivation in lower IF panels). 200 PM/M per condition were counted in 2 experiments. Error bars represent s.d. **: p < 0.001, χ2 test. Red asterisks indicate significant differences with respect to DMSO controls, and black asterisks significant differences between Aurora-Ai mitoses with active or inactive Eg5. Scale bar: 10 μm

    Mol Cancer 2011 10, 131. Alisertib (MLN8237) purchased from Selleck.

    Alisertib inhibits AURKA and AURKB in a concentration-dependent manner. (a) Alisertib induces G 2 /M delay or genome reduplication. HeLa cells were exposed to buffer or the indicated concentrations of Alisertib. After 24 h, the cells were harvested and analyzed with flow cytometry. The positions of 2N, 4N and 8N DNA contents are indicated. (b) Alisertib delays mitotic exit or induces slippage. HeLa cells stably expressing histone H2B-GFP were exposed to buffer or the indicated concentrations of Alisertib. Individual cells were then tracked for 24 h with time-lapse microscopy. Each horizontal bar represents one cell (n ¼ 50). Key: light gray ¼ interphase; black ¼ mitosis (from DNA condensation to anaphase or mitotic slippage); dark gray ¼ interphase after mitotic slippage; truncated bars ¼ cell death. (c) Different concentrations of Alisertib are involved in delaying mitotic exit and inducing slippage. Live-cell imaging of cells treated with Alisertib was described in panel (b). The duration of mitosis (mean±90% confidence interval) and the percentage of cells that underwent mitotic slippage during the imaging period was quantified. (d) Alisertib promotes apoptosis in a concentration-dependent manner. HeLa cells were incubated with the indicated concentrations of Alisertib for 48 h. The cells were then harvested and analyzed with flow cytometry. (e) Concentration-dependent cytotoxicity of Alisertib. HeLa cells were cultured in the presence of the indicated concentrations of Alisertib for 48 h. The number of live and dead cells was analyzed with trypan blue exclusion assay. (f) Concentration-dependent suppression of long-term survival by Alisertib. HeLa cells were seeded on 60-mm culture plates and grown in the presence of 250 n M or 1 m M of Alisertib. After 24 h, the cells were washed gently and propagated in normal medium for another 10–12 days. Colonies were fixed and stained with crystal violet solution (examples of the plates are shown). Average±s.d. from three independent experiments. (g) Both AURKA and AURKB are inhibited by Alisertib.Mitotic HeLa cells were obtained by exposure to nocodazole for 16 h followed by mechanical shake off. The cells were incubated with the indicated concentrations of Alisertib for 2 h. Lysates were then prepared and activated phospho-AURKAThr288 and AURKBThr232were detected with immunoblotting. The asterisk indicates the position of an AURKB-like protein (the same throughout this study). Uniform loading was confirmed by immunoblotting for actin. In this assay, nocodazole and MG132 (a proteasome inhibitor) were added to prevent the cells from exiting mitosis. Accordingly, the total AURKA and AURKB levels remained constant throughout the experiment. (h) Alisertib prevents activation of AURKA and AURKB. HeLa cells were incubated with the indicated concentrations of Alisertib for 8 h. Nocodazole was then added for another 6 h to trap cells that entered mitosis. Lysates were prepared and analyzed with immunoblotting. Actin analysis was included to assess loading and transfer.

    Oncogene 2014 33, 3550-60. Alisertib (MLN8237) purchased from Selleck.

  • Inhibition of Aurora A (12.5 nM) by MLN8054 or MLN8237 was assessed in duplicate radiometric assays containing 100 μM [γ-32P] ATP and quantified by p81 phosphocellulose assay and scintillation counting. Kinase activity is reported as a percentage of control calculated from duplicate incubations containing 2.5% (v/v) DMSO. IC50 values represent the mean ±SEM calculated from two independent experiments.

     

     

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

    The effects of T217D and T217N Aurora A mutations were directly compared to WT Aurora A-expressing cells. Each well was treated with either DMSO or 500 nM MLN8054 (E), or 30 nM MLN8237 (F) on day one of the experiment and cells were cultured for 8 days, at which point they were fixed. For all colony assays, an area encompassing >90 % of the colonies per dish is shown. Similar results were seen in two independent duplicate experiments.

    ACS Chem Biol 2010 5, 563-576. Alisertib (MLN8237) purchased from Selleck.

  • B, drug-treated cells were also stained with DAPI to visualize nuclear DNA and analyzed with a microscope equipped with a fluorescence digital CCD camera. Representative results are shown. Bar, 40 μm.

    J Biol Chem, 2017, 292(5):1910-1924. Alisertib (MLN8237) purchased from Selleck.

    C, Fry depletion decreases the level of Thr-210 phosphorylation of Plk1 on spindle poles. HeLa cells transfected with siRNAs were cultured in growth medium for 12 h and in thymidine-containing medium for 36 h. They were then released from thymidine arrest for 12 h before being fixed and stained with anti-Plk1 pT210 ( green) and anti-pericentrin (red) antibodies. DNA was stained with TO-PRO-3 ( blue ). For Aurora A inhibition, after release from thymidine block for 10 h, HeLa cells transfected with control siRNA were incubated for2h in medium containing MLN8237 (100 nM) and MG132 (10 μM). Magnified images of the white boxes are also shown. Scale bar ,5 μm.

    J Biol Chem 2012 287, 27670-81. Alisertib (MLN8237) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.
Features First orally available inhibitor of Aurora A.
Targets
Aurora A [1]
(Cell-free assay)
1.2 nM
In vitro

MLN8237 shows >200-fold higher selectivity for Aurora A than the structurally related Aurora B with an IC50 of 396.5 nM, and does not have any significant activity against 205 other kinases. [1] MLN8237 (0.5 μM) treatment inhibits the phosphorylation of Aurora A in MM1.S and OPM1 cells, without affecting the Aurora B mediated histone H3 phosphorylation. MLN8237 significantly inhibits cell proliferation in multiple myeloma (MM) cell lines with IC50 values of 0.003-1.71 μM. MLN8237 displays more potent anti-proliferation activity against primary MM cells and MM cell lines in the presence of BM stroma cells, as well as IL-6 and IGF-1 than against MM cells alone. MLN8237 (0.5 μM) induces 2- to 6-fold increase in G2/M phase in primary MM cells and cell lines, as well as significant apoptosis and senescence, involving the up-regulation of p53, p21 and p27, as well as PARP, caspase 3, and caspase 9 cleavage. In addition, MLN8237 shows strong synergistic anti-MM effect with dexamethasone, as well as additive effect with doxorubicin and bortezomib. [2] MLN8237 (0.5 μM) treatment causes the inhibition of colony formation of FLO-1, OE19, and OE33 esophageal adenocarinoma cell lines, and induces a significant increase in the percentage of polyploid cells, and subsequently an increase in the percentage of cells in the sub-G1 phase, which can be further enhanced in combination with cisplatin (2.5 μM), involving the higher induction of TAp73β, PUMA, NOXA, cleaved caspase-3, and cleaved PARP as compared with a single-agent treatment. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 Mo\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDJSFBNOC53IN88US=> NFHFNVA4OiCq NG\XUnFFVVOR NEL2T|lKSzVyPUCuNFQh|ryP M1;OUFI3OTN4Nki0
LS174T MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYW2NHhGOC53IN88US=> NYjGNlBTPzJiaB?= M4rHcWROW09? NFH0WIdKSzVyPUCuNFUh|ryP MkHXNlYyOzZ4OES=
T84 M2XN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;sNE42KM7:TR?= Mof5O|IhcA>? MmHiSG1UVw>? NV\HVnpWUUN3ME2wMlA6KM7:TR?= MV6yOlE{PjZ6NB?=
LS180 NFT2bYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLEOlYxNjVizszN NIDUcmE4OiCq M1Pa[mROW09? NIHpNYlKSzVyPUGg{txO NV32b4lvOjZzM{[2PFQ>
SW948 NFfoZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PKTFAvPSEQvF2= Mo\0O|IhcA>? MlfKSG1UVw>? NIfkWHpKSzVyPUGg{txO NEL3UoEzPjF|Nk[4OC=>
HCT15 NH7FXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXLR4hUOC53IN88US=> NEfa[Zc4OiCq Mk[5SG1UVw>? M1fVfmlEPTB:MD60JO69VQ>? MX2yOlE{PjZ6NB?=
DLD-1 NIDFZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M121NVAvPSEQvF2= NWXufGZ7PzJiaB?= M2i1RmROW09? MYHJR|UxRDBwODFOwG0> MWeyOlE{PjZ6NB?=
MIP-101 MoThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUWwMlUh|ryP MlvIO|IhcA>? NY\4WWN3TE2VTx?= NWriWZFxUUN3ME2xJO69VQ>? NHH1O4czPjF|Nk[4OC=>
SNU1544 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HhflAvPSEQvF2= M1jhb|czKGh? NETVUpdFVVOR MXTJR|UxRTFizszN NF:zT2EzPjF|Nk[4OC=>
OCI-Ly10 NGDodZZEgXSxdH;4bYMhSXO|YYm= NVnnSnRSPzJiaB?= NFLBco5FVVOR NXK4XogzUUN3ME2wMlA2QCEQvF2= NHLKc4MzPTh5OEOzNS=>
SU-DHL2 Mlz5R5l1d3SxeHnjJGF{e2G7 NVuzS5p[PzJiaB?= M3mzeWROW09? M2nOc2lEPTB;MD6wNUDPxE1? NVqyU2Q3OjV6N{izN|E>
OCI-LY7 NEfsTI9EgXSxdH;4bYMhSXO|YYm= MYO3NkBp NFP4T2dFVVOR Mn75TWM2OD1yLkC4NUDPxE1? MVmyOVg4QDN|MR?=
SU-DHL6 M2DPNWN6fG:2b4jpZ{BCe3OjeR?= NYDscXBxPzJiaB?= NFzxR3VFVVOR M4nTemlEPTB;MD60PFIh|ryP NEW2elczPTh5OEOzNS=>
Jeko-1 NWXyV5hHS3m2b4TvfIlkKEG|c3H5 NWrlTY5JPzJiaB?= NX3GZoxITE2VTx?= M{DQUmlEPTB;MD6wNlkh|ryP NFfVV|gzPTh5OEOzNS=>
JVM-2 NI\lPXFEgXSxdH;4bYMhSXO|YYm= NXz6dIlSPzJiaB?= NX:w[opvTE2VTx?= M1XS[mlEPTB;MD6wNUDPxE1? NXLocHhmOjV6N{izN|E>
Rec-1 NHOzRXlEgXSxdH;4bYMhSXO|YYm= M2LGTVczKGh? M3PmS2ROW09? MWLJR|UxRTBwMEi3JO69VQ>? MX[yOVg4QDN|MR?=
Z-138 M1rid2N6fG:2b4jpZ{BCe3OjeR?= M2LrcFczKGh? NWm2cm9MTE2VTx?= NFTmUJVKSzVyPUCuNFE{KM7:TR?= MUiyOVg4QDN|MR?=
H9 MYDDfZRwfG:6aXOgRZN{[Xl? NXnyN2lYPzJiaB?= NF3LU41FVVOR NH;k[lZKSzVyPUCuOkDPxE1? M3;KXVI2QDd6M{Ox
HH MmH6R5l1d3SxeHnjJGF{e2G7 MmPzO|IhcA>? NF20[VlFVVOR MVfJR|UxRTBwNzFOwG0> NHTIeYwzPTh5OEOzNS=>
DND41 NHX6[21EgXSxdH;4bYMhSXO|YYm= NYXqUYJTPzJiaB?= MlXNSG1UVw>? M1riemlEPTB;MD6xJO69VQ>? MW[yOVg4QDN|MR?=
CCL119 MUfDfZRwfG:6aXOgRZN{[Xl? NHHKfXY4OiCq MYTEUXNQ NH[2e3ZKSzVyPUCuNFYzKM7:TR?= MXGyOVg4QDN|MR?=
J.Cam 1.6 MkG1R5l1d3SxeHnjJGF{e2G7 M2DOU|czKGh? M4nsO2ROW09? M3[1N2lEPTB;MD6xNFUh|ryP M{Xo[VI2QDd6M{Ox
Sup-T1 NWjYOZlkS3m2b4TvfIlkKEG|c3H5 MWG3NkBp NUXYNG9{TE2VTx?= MnLaTWM2OD1{LkG0NkDPxE1? NGXFVY8zPTh5OEOzNS=>
Tib 152 M2T4TWN6fG:2b4jpZ{BCe3OjeR?= NWLjeI5SPzJiaB?= MmnOSG1UVw>? MWDJR|UxRTBwODFOwG0> NUHZZ2lZOjV6N{izN|E>
MCF7 NV[4VXhPTnWwY4Tpc44hSXO|YYm= MVi1JO69VQ>? MnjUNlQhcA>? NVnrV256TE2VTx?= MkPHTY5lfWOnczDHNk9OKGG{cnXzeC=> MWGyOVg{PDRyMR?=
MDA-MB-231 NI\vO4lHfW6ldHnvckBCe3OjeR?= NVm5fIpQPSEQvF2= MUOyOEBp MmnjSG1UVw>? NYDyN4FkUW6mdXPld{BIOy:PIHHydoV{fA>? NE\tfmgzPTh|NESwNS=>
MCF7 NXfqVGtCTnWwY4Tpc44hSXO|YYm= MYm1JO69VQ>? MUmyOEBp NWXVVZM4TE2VTx?= NUXrNox[TGWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJGNFUzFxQ1TDNi=> M3nIXFI2QDN2NECx
MCF7 MoO2SpVv[3Srb36gRZN{[Xl? M{j0d|Uh|ryP NVXiWJN[OjRiaB?= M3rHU2ROW09? M4HK[GRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDDSGsz NGjQNmYzPTh|NESwNS=>
MCF7 Mm\6SpVv[3Srb36gRZN{[Xl? NGj2cZY2KM7:TR?= MWSyOEBp MUnEUXNQ MnfkSIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIHP5Z4xqdiCEMR?= MnfZNlU5OzR2MEG=
MCF7 Mom5SpVv[3Srb36gRZN{[Xl? NGGwenQ2KM7:TR?= M{e0clI1KGh? M2rBeGROW09? Mmi0TY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE> M2LWd|I2QDN2NECx
MCF7 NX\4U3BFTnWwY4Tpc44hSXO|YYm= MlHUOUDPxE1? NXfYWFB5OjRiaB?= NGrDWFhFVVOR NF3zW3lKdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG= NIjJRlEzPTh|NESwNS=>
MDA-MB-231 NVLrSpNSTnWwY4Tpc44hSXO|YYm= MnvGOUDPxE1? NH3VfWozPCCq Moi2SG1UVw>? MkDNSIVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|EwS0SFMh?= M4X0XlI2QDN2NECx
MDA-MB-231 NIG4S5ZHfW6ldHnvckBCe3OjeR?= NEC3[lcyKM7:TR?= NXnJRZl2OjRiaB?= M3XERmROW09? Ml3wTY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIFPET|I> MknYNlU5OzR2MEG=
MDA-MB-231 MYnGeY5kfGmxbjDBd5NigQ>? MYm1JO69VQ>? MojONlQhcA>? NX3wWGNXTE2VTx?= M3LmZmRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjDjfYNtcW5iQkG= NIe0VWMzPTh|NESwNS=>
MDA-MB-231 MVnGeY5kfGmxbjDBd5NigQ>? MWi1JO69VQ>? MoP5NlQhcA>? M3;vb2ROW09? Mlq4TY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:oIICyNUBY[WZzL1PpdFE> NY\VSFhmOjV6M{S0NFE>
MDA-MB-231 M1vDWGZ2dmO2aX;uJGF{e2G7 M3LYblUh|ryP MW[yOEBp M2e0PGROW09? NHTCPI9KdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gcIV3\Wxib3[gdFI4KEurcEG= NVrLU4lYOjV6M{S0NFE>
MDA-MB-231 MoHLSpVv[3Srb36gRZN{[Xl? M33ZblUh|ryP NYf2VVBHOjRiaB?= NYHmS2kyTE2VTx?= NWLtdoZKUW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mJJA2Ow>? M2P1WVI2QDN2NECx
MCF7 MXrBdI9xfG:|aYOgRZN{[Xl? M3G0clUh|ryP M1\6WFI1KGh? NUTVfmZzTE2VTx?= NUK0fJI6UW6mdXPld{BieG:ydH;0bYMh\GWjdHi= NH3HPGIzPTh|NESwNS=>
MDA-MB-231 MX;BdI9xfG:|aYOgRZN{[Xl? NELvcm02KM7:TR?= M1LyOVI1KGh? NUnmb4ZYTE2VTx?= MkTlTY5lfWOnczDhdI9xfG:2aXOg[IVifGh? M2\rflI2QDN2NECx
MCF7 MnTRSpVv[3Srb36gRZN{[Xl? NYqx[olKOSEQvF2= MVy3NkBp NV3McpBmTE2VTx?= M2LwOGlv\HWlZYOgZZV1d3CqYXfpZ{Bl\WG2aB?= Ml\pNlU5OzR2MEG=
MDA-MB-231 MX7GeY5kfGmxbjDBd5NigQ>? NELvXmoyKM7:TR?= NInSfpY4OiCq NUO2OotwTE2VTx?= NIPWcmhKdmS3Y3XzJIF2fG:yaHHnbYMh\GWjdHi= NVz4TlNSOjV6M{S0NFE>
U-2 OS NYO1eoIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGmzSVM2OCEQvF2= MV2yOEBp Ml7NSG1UVw>? M3rycmlEPTB;MU[uOkDPxE1? M371c|I2Pzl{OEGx
MG-63 NXn3fIFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTBOVAh|ryP MnfjNlQhcA>? MXXEUXNQ MVXJR|UxRTlwNTFOwG0> MWOyOVc6OjhzMR?=
U-2 OS MW\BdI9xfG:|aYOgRZN{[Xl? MVy1JO69VQ>? NITFWVczPCCq MVXEUXNQ Moj5TY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=> NV7XOnFKOjV5OUK4NVE>
MG-63 MonyRZBweHSxc3nzJGF{e2G7 NF;1b4k2KM7:TR?= M2PSb|I1KGh? MnHUSG1UVw>? Mnr0TY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=> Ml;1NlU4QTJ6MUG=
U-2 OS NWewRmZ1TnWwY4Tpc44hSXO|YYm= MoDnOUDPxE1? M2C2eVI1KGh? MkjxSG1UVw>? NFvlRY9Rem:vb4Tld{BifXSxcHjh[4lkKGOnbHyg[IVifGh? M1j5SlI2Pzl{OEGx
MG-63 M3TBV2Z2dmO2aX;uJGF{e2G7 M2joOVUh|ryP NHS4V3czPCCq NFO1cY1FVVOR MoLWVJJwdW:2ZYOgZZV1d3CqYXfpZ{Bk\WyuIHTlZZRp MVmyOVc6OjhzMR?=
PANC-1 NHfRU41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfYUJQ2OCEQvF2= NH3LblkzPCCq NGOzXmlFVVOR M4G3SmlEPTB;Nz6xJO69VQ>? MXqyOVY{OjJ{NR?=
BxPC-3 NYXme3p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17Ze|UxKM7:TR?= M1T5RlI1KGh? NWD5b2dETE2VTx?= NV2wR4toUUN3ME22Mlgh|ryP MnfWNlU3OzJ{MkW=
PANC-1 NFG5W|dHfW6ldHnvckBCe3OjeR?= NIniNYU2KM7:TR?= NWXsXoV{OjRiaB?= M2\RXmROW09? M1TRfmlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hTzJxTTDwbIF{\Q>? NEPJXYwzPTZ|MkKyOS=>
BxPC-3 MVPGeY5kfGmxbjDBd5NigQ>? MWm1JO69VQ>? M1fpN|I1KGh? NWq1dWo4TE2VTx?= NIXLXFBKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIlvKEd{L12gdIhie2V? Mn7DNlU3OzJ{MkW=
PANC-1 M3TXTGZ2dmO2aX;uJGF{e2G7 MlKzOUDPxE1? Mn\NNlQhcA>? M1fLZ2ROW09? NEHOdm5KdmS3Y3XzJIF2fG:yaHHnbYMh[2WubDDk[YF1cA>? NVzTVnJIOjV4M{KyNlU>
BxPC-3 NGfObVZHfW6ldHnvckBCe3OjeR?= NV;6WHRXPSEQvF2= NF\tTmczPCCq MnrkSG1UVw>? MVfJcoR2[2W|IHH1eI9xcGGpaXOgZ4VtdCCmZXH0bC=> NUTK[VhkOjV4M{KyNlU>
SKOV3 M3fpOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXixV3JwOTByIN88US=> NVnrRpNNOjRiaB?= NISwR2hFVVOR NVnhemdZUUN3ME2yNE41QCEQvF2= MkXONlU3OjR5NUC=
OVCAR4 MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH1[FUyODBizszN NIqyboczPCCq MmC2SG1UVw>? NXHjUWFzUUN3ME2yNk4yOyEQvF2= M4P1OVI2PjJ2N{Ww
SKOV3 NF[zUZBHfW6ldHnvckBCe3OjeR?= NFXudYg2KM7:TR?= NWX5fGZXPzJiaB?= M3uzUGROW09? Ml7zTY5lfWOnczDHNk9OKGG{cnXzeC=> Mki5NlU3OjR5NUC=
OVCAR4 NWH4NJF3TnWwY4Tpc44hSXO|YYm= M1XFdlUh|ryP NEnKSnE4OiCq MYPEUXNQ NUPCUmw2UW6mdXPld{BIOi:PIHHydoV{fA>? NEHmc3ozPTZ{NEe1NC=>
SKOV3 NVy1bFNCSXCxcITvd4l{KEG|c3H5 M{jwcVUh|ryP NV63OYl1OjRiaB?= MkTYSG1UVw>? NEHyTXBKdmS3Y3XzJIFxd3C2b4Ppdy=> M1rHbFI2PjJ2N{Ww
OVCAR4 M13McWFxd3C2b4Ppd{BCe3OjeR?= MUi1JO69VQ>? MoLlNlQhcA>? MkXISG1UVw>? M4f3R2lv\HWlZYOgZZBweHSxc3nz NFLodI8zPTZ{NEe1NC=>
AGS MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUeyOUDPxE1? NFvwPIUzPCCq Mmj5SG1UVw>? MmXvTWM2OD1zOT6wPUDPxE1? NX7TOFA3OjV4MEm5NlM>
NCI-N78 MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDpOY9KOjVizszN MWqyOEBp Mo\hSG1UVw>? NHHzeZZKSzVyPUK2MlM{KM7:TR?= MV2yOVYxQTl{Mx?=
AGS M{L4NGFxd3C2b4Ppd{BCe3OjeR?= NUPhWmNjPSEQvF2= NX;6R2U5OjRiaB?= MYTEUXNQ NV7UOHF{UW6mdXPld{BieG:ydH;zbZM> M4nDRlI2PjB7OUKz
NCI-N78 MkjvRZBweHSxc3nzJGF{e2G7 NVPEN|JOPSEQvF2= NVe1ToRxOjRiaB?= M{jzS2ROW09? NG[0V3BKdmS3Y3XzJIFxd3C2b4Ppdy=> M3\jRVI2PjB7OUKz
AGS NH3LZXhHfW6ldHnvckBCe3OjeR?= NWrnVnBtPSEQvF2= M4jVWlI1KGh? MVTEUXNQ MlqyTY5lfWOnczD0bIUh[XW2b4DoZYd6 M{jjcVI2PjB7OUKz
NCI-N78 NXjweYtnTnWwY4Tpc44hSXO|YYm= M1jrNVUh|ryP NIjiPZkzPCCq NF3qUZZFVVOR NYrCS2tIUW6mdXPld{B1cGViYYX0c5Bp[We7 NW\lWHZOOjV4MEm5NlM>
HSC-3 NUOybIx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;4b2xTOSEQvF2= NH75SFg1QCCq NXPnUYxoUUN3ME2wMlU1KM7:TR?= NXXES5J7OjV|Nk[xOFM>
GB30 M{LzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrn[IYyKM7:TR?= MWC3JIQ> NEPXNHhFVVOR M3LVV2lEPTB;MD6wNVEh|ryP MoXjNlUyODZ2Mki=
GB9 NWPvPHZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH2dmxNOSEQvF2= MWK3JIQ> MlTZSG1UVw>? Mn;QTWM2OD1yLkCyOEDPxE1? NV\jeoxrOjVzME[0Nlg>
GB169 NILGXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fSc|Eh|ryP NVfBcXJTPyCm M{HjeWROW09? MXTJR|UxRTBwMEOyJO69VQ>? M4ruSlI2OTB4NEK4
T24 NYXlTnFPTnWwY4Tpc44hSXO|YYm= NWDqV|c4OSEQvF2= NHi5NZg1QCCq MWTEUXNQ M3fXU2lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= NFTMTYMzOzRyM{[zNy=>
RT4 MYnGeY5kfGmxbjDBd5NigQ>? MVqxJO69VQ>? M4nNZ|Q5KGh? M2nCVWROW09? NHfhcndKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0 NILlWlIzOzRyM{[zNy=>
UM-UC-3 MV7GeY5kfGmxbjDBd5NigQ>? NVfpWHpkOSEQvF2= MY[0PEBp M4TISWROW09? M2C5UWlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MXqyN|QxOzZ|Mx?=
T24 MoS0RZBweHSxc3nzJGF{e2G7 NH22cHo{NjF4IN88US=> M{\me|k3KGh? MWjEUXNQ MYDJR|UxRTBwMEOwOkDPxE1? NWPQ[2tMOjN2MEO2N|M>
RT4 NH3hemRCeG:ydH;zbZMhSXO|YYm= NH\qPG4{NjF4IN88US=> MVi5OkBp MVLEUXNQ NH7BXoxKSzVyPUCuNVE6QCEQvF2= NUHvXItsOjN2MEO2N|M>
UM-UC-3 NYrRV3VrSXCxcITvd4l{KEG|c3H5 MVezMlE3KM7:TR?= NI\YPJM6PiCq MkXzSG1UVw>? NXTT[I1sUUN3ME2wMlA1PDlizszN MXKyN|QxOzZ|Mx?=
OVCAR-5 MW\GeY5kfGmxbjDBd5NigQ>? M{DJS|UxKG6P MnzvTY5pcWKrdIOgZ4VtdCCvaXfyZZRqd25? MnfkNlM{OzR|Mke=
SKOV3ip2 NUPxNYJDTnWwY4Tpc44hSXO|YYm= NX;icFIzPTBibl2= NHrHZ5pKdmirYnn0d{Bk\WyuIH3p[5JifGmxbh?= MmHrNlM{OzR|Mke=
S462 MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfyNVAxKM7:TR?= M2D2TlczKGh? NXq0RotiTE2VTx?= Mli1RZR1\W63YYTld{Bk\WyuIHfyc5d1cA>? MkXyNlM{OjhzMUS=
2884 M2Syc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rRVFExOCEQvF2= NUjWflZSPzJiaB?= NHnpeIdFVVOR NHfnRpJCfHSnboXheIV{KGOnbHyg[5Jwf3Sq M3HldFI{OzJ6MUG0
2885 NG\BOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV2xNFAh|ryP MXy3NkBp NGDSVFlFVVOR NYnJ[YZmSXS2ZX71ZZRmeyClZXzsJIdzd3e2aB?= MmPyNlM{OjhzMUS=
CRL-2396 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTTNVAxKM7:TR?= M4DEPZdifGW{ M2PuT2lEPTB;MD6wPVIh|ryP M2OwS|I{OTV|NUK0
TIB-48 NYjxXndXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TUOlExOCEQvF2= MYH3ZZRmeg>? M1q1N2lEPTB;MD6wPFgh|ryP MljCNlMyPTN3MkS=
CRL-2396 MmG3R5l1d3SxeHnjJGF{e2G7 MnvWNUDPxE1? NXW0c5RiPDhiaB?= NGDD[JZ4[XSnch?= M1n2SWlv\HWlZYOgZZBweHSxc3nz NF7LUIozOzF3M{WyOC=>
TIB-48 NEjCN4dEgXSxdH;4bYMhSXO|YYm= MX2xJO69VQ>? M3naelQ5KGh? MXj3ZZRmeg>? NWjLS3B2UW6mdXPld{BieG:ydH;zbZM> M1nYZ|I{OTV|NUK0
AGS M2TNbGN6fG:2b4jpZ{BCe3OjeR?= NFjBU|gxNjVizszN NX;0Z2JpOjRiaB?= MUfEUXNQ NWX1SYpxTGWlcnXhd4V{KGOnbHygd5Vzfmm4YXy= M2Xi[|IzQTd{NkGx
FLO-1 M{DSWWN6fG:2b4jpZ{BCe3OjeR?= M{X4XlAvPSEQvF2= MYSyOEBp MnHISG1UVw>? M37Fe2Rm[3KnYYPld{Bk\WyuIIP1dpZqfmGu MUmyNlk4OjZzMR?=
OE33 Ml3OR5l1d3SxeHnjJGF{e2G7 M4m4NlAvPSEQvF2= M1v3N|I1KGh? MYXEUXNQ NGPIPZJF\WO{ZXHz[ZMh[2WubDDzeZJ3cX[jbB?= M4LmelIzQTd{NkGx
SKLMS MXLDfZRwfG:6aXOgRZN{[Xl? Mnv3O|Uhdk1? NFfvO4s6PiCq M4PyOmlv\HWlZYOgZZBweHSxc3nz NIWyOnEzOjh{MUm5Oy=>
Leio285 MVjDfZRwfG:6aXOgRZN{[Xl? MV23OUBvVQ>? NU\jUnlxQTZiaB?= MWDJcoR2[2W|IHHwc5B1d3Orcx?= MoC3NlI5OjF7OUe=
Mes-Sa NUDrXZllS3m2b4TvfIlkKEG|c3H5 M3H2Z|c2KG6P MkHzPVYhcA>? MlLxTY5lfWOnczDhdI9xfG:|aYO= MoT5NlI5OjF7OUe=
DAOY NWnDNnppS3m2b4TvfIlkKEG|c3H5 MV2xNEDPxE1? NV2wPGZwPzJiaB?= M{jYOGROW09? M{jBVGlEPTB;MD6wOEDPxE1? NInwRnQzOjZ4OUOzOS=>
IMR32 NUnu[I1TS3m2b4TvfIlkKEG|c3H5 MmnJNVAh|ryP MWS3NkBp NYLTXGFJTE2VTx?= NHLCWHdKSzVyPUCuNFMh|ryP Mlf5NlI3Pjl|M{W=
Molt-4 M37U[mN6fG:2b4jpZ{BCe3OjeR?= NYixN5pLOTBizszN MXm3NkBp MWrEUXNQ NWThXlZxUUN3ME2wMlAzKM7:TR?= MoTYNlI3Pjl|M{W=
MOLM-13 MlHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUezJO69VQ>? Mk[xO|IhcA>? MmH6SIlucW6rc3jld{Bk\WyuII\pZYJqdGm2eR?= NIPhcnkzOjR6OEK0PS=>
HL-60 NVfZcFNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XC[FMh|ryP NYW5cY45PzJiaB?= M1X3NmRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= M2SxZ|IzPDh6MkS5
MV4-11 Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vU[VMh|ryP NXnR[ZRtPzJiaB?= NV7YW41qTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> NHPMVJgzOjR6OEK0PS=>
SKM-1 MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn32N{DPxE1? Mk\VO|IhcA>? NU[4WmRbTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> M33CR|IzPDh6MkS5
SH2 NHrWb|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LhXVMh|ryP NHTENJA4OiCq MUDEbY1qdmm|aHXzJINmdGxidnnhZoltcXS7 NV:4XZl1OjJ2OEiyOFk>
NOMO-1 NYrJZWVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P1TlMh|ryP MUC3NkBp NVz3WYVGTGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> MWqyNlQ5QDJ2OR?=
OCL-AML2 Ml7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37UUlMh|ryP NWfCXWhGPzJiaB?= NWnUS4R4TGmvaX7pd4hmeyClZXzsJJZq[WKrbHn0fS=> MnPJNlI1QDh{NEm=
PL-21 NHrsPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:zJO69VQ>? Mom1O|IhcA>? NH\DTHdFcW2rbnnzbIV{KGOnbHygeoli[mmuaYT5 NXPNbGNZOjJ2OEiyOFk>
KG-1 NYfzOmlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPmbpF2OyEQvF2= NHvCZ4Y4OiCq M1TtemRqdWmwaYPo[ZMh[2WubDD2bYFjcWyrdIm= MWiyNlQ5QDJ2OR?=
A172 MUPDfZRwfG:6aXOgRZN{[Xl? MkHhNVAxKM7:TR?= MYOyOEBp NF3Zbm5FVVOR NEXjbIZKSzVyPUCuNVIxKM7:TR?= NWW4foREOjJ{N{SzPVk>
U87 NWPG[495S3m2b4TvfIlkKEG|c3H5 NVzDeJN3OTByIN88US=> MlHKNlQhcA>? M4DQTmROW09? M1m5ZmlEPTB;MD6xNFUh|ryP NHLUWGEzOjJ5NEO5PS=>
U251 MYTDfZRwfG:6aXOgRZN{[Xl? NH24XYQyODBizszN NW\rfGRSOjRiaB?= NFnBS5RFVVOR M1zxN2lEPTB;MD6xNFAh|ryP MYiyNlI4PDN7OR?=
T98 NIfNR4VEgXSxdH;4bYMhSXO|YYm= MYOxNFAh|ryP NU\vOGh2OjRiaB?= MmfPSG1UVw>? M4DuemlEPTB;MD6xNlUh|ryP MWKyNlI4PDN7OR?=
LN18 M17TZ2N6fG:2b4jpZ{BCe3OjeR?= NXjabXl[OTByIN88US=> MWqyOEBp MYPEUXNQ NUfIXpRnUUN3ME2wMlIyOCEQvF2= NGjxcZozOjJ5NEO5PS=>
LN443 MnXqR5l1d3SxeHnjJGF{e2G7 Mny4NVAxKM7:TR?= M4XEOVI1KGh? NUP2SmxkTE2VTx?= NVj0VHptUUN3ME2wMlIzOCEQvF2= MUCyNlI4PDN7OR?=
HF66 NVvVNpdQS3m2b4TvfIlkKEG|c3H5 M1jHV|ExOCEQvF2= NHf6OZMzPCCq M1PQU2ROW09? MUHJR|UxRTBwMkK1JO69VQ>? MofsNlIzPzR|OUm=
HF2303 NESycHZEgXSxdH;4bYMhSXO|YYm= MoPSNVAxKM7:TR?= NH2xSGYzPCCq NH:4OppFVVOR MVHJR|UxRTBwME[wJO69VQ>? NU\vWW9XOjJ{N{SzPVk>
HF2359 NXj4[IxDS3m2b4TvfIlkKEG|c3H5 NFnYRpQyODBizszN NXzvd3F2OjRiaB?= NIf2SY1FVVOR NXrtbHc{UUN3ME2wMlA3OCEQvF2= MoO3NlIzPzR|OUm=
HF2414 NUHXR2ZuS3m2b4TvfIlkKEG|c3H5 NIPLRpQyODBizszN M1LmNVI1KGh? MVXEUXNQ M3\yZ2lEPTB;MD6wPFAh|ryP M3XNWlIzOjd2M{m5
A-673 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nYOFExKM7:TR?= Ml3sPVYhcA>? MnnsSG1UVw>? M{mwcWlEPTB;MD6wN|Ih|ryP NFTlTJgzOTR2OEW5NS=>
TC-32 M323dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEG0[JYyOCEQvF2= M4rmPFk3KGh? NWjTPJJ4TE2VTx?= MUPJR|UxRTBwMEO5JO69VQ>? M1j3SlIyPDR6NUmx
TC-71 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHFNVAh|ryP NEH1OZI6PiCq M2rSUWROW09? NGmxepVKSzVyPUCuNVAzKM7:TR?= NFPDVnMzOTR2OEW5NS=>
SK-N-MC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrKNVAh|ryP NE\CS3k6PiCq MnPsSG1UVw>? NVLJU4xXUUN3ME2wMlA4OiEQvF2= MYCyNVQ1QDV7MR?=
CHLA-9 MlzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Ht[VExKM7:TR?= MWm5OkBp NVvENVVFTE2VTx?= M3jjeGlEPTB;MD6wNVgh|ryP Ml;wNlE1PDh3OUG=
CHLA-10 MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfSNVAh|ryP NX[5VItUQTZiaB?= MnXDSG1UVw>? NVzBNHI5UUN3ME2wMlA3OCEQvF2= MV6yNVQ1QDV7MR?=
CHLA-25 MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\jR|ExKM7:TR?= NFLYVYk6PiCq NUHZWIVCTE2VTx?= MlP1TWM2OD1yLkG2PEDPxE1? NH3SOXMzOTR2OEW5NS=>
CHLA-32 M161XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTMU3N{OTBizszN NVHEeYZoQTZiaB?= MlzBSG1UVw>? M{\HOWlEPTB;MD6xN|Yh|ryP NGLEZWozOTR2OEW5NS=>
CHLA-56 MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCxNEDPxE1? MVO5OkBp NVHiS5NETE2VTx?= MlHBTWM2OD1zMDFOwG0> NH62e5kzOTR2OEW5NS=>
CHLA-258 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1njUVExKM7:TR?= NXfnToVCQTZiaB?= M2DlSWROW09? NUnkVppUUUN3ME2wMlE{OiEQvF2= M4LkSVIyPDR6NUmx
COG-E-352 NVi1XWN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG0NVAh|ryP NIXpe2M6PiCq MUfEUXNQ M1nySGlEPTB;MD6wOFMh|ryP M1vMRlIyPDR6NUmx
CHLA-90 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[xNEDPxE1? NYHzb5I2QTZiaB?= MYTEUXNQ NF3VTolKSzVyPUCuNFYyKM7:TR?= MXmyNVQ1QDV7MR?=
CHLA-119 M1rqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[xNEDPxE1? MVu5OkBp MVzEUXNQ M132b2lEPTB;MD6wNlIh|ryP NFr0T4QzOTR2OEW5NS=>
CHLA-122 NXHaXVA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnGNVAh|ryP NWTVV49EQTZiaB?= NGD6TJZFVVOR M4DKRmlEPTB;MD6wNVkh|ryP NVy4N3d4OjF2NEi1PVE>
CHLA-136 NEDqPFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme4NVAh|ryP Mke0PVYhcA>? Ml7SSG1UVw>? Ml75TWM2OD1yLkCzPUDPxE1? MlXCNlE1PDh3OUG=
CHLA-140 NGDzdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrTTocyOCEQvF2= Mn\BPVYhcA>? NES3R2JFVVOR NV;iXpFmUUN3ME2wMlAzPiEQvF2= NUf1R2ZYOjF2NEi1PVE>
LA-N-6 M1;Qe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonVNVAh|ryP MYK5OkBp NHHHS2FFVVOR NGLHXINKSzVyPUCuNFU1KM7:TR?= MVqyNVQ1QDV7MR?=
NB-1643 NULrZWRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWKyNXBUOTBizszN NU\POHdSQTZiaB?= NWX1PGlGTE2VTx?= NELFOGVKSzVyPUCuNFM4KM7:TR?= M37MXFIyPDR6NUmx
NB-EBc1 NWezemV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvlTXNQOTBizszN NUXhPWNHQTZiaB?= NUnwc3U5TE2VTx?= NH;PSVhKSzVyPUCuNFUxKM7:TR?= NIXDRnczOTR2OEW5NS=>
SK-N-BE-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUKxNEDPxE1? MmTWPVYhcA>? MnHJSG1UVw>? NGPJWHdKSzVyPUCuNFI5KM7:TR?= MV:yNVQ1QDV7MR?=
SK-N-BE-2 M2nTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLaNVAh|ryP NYjhXZd4QTZiaB?= NUDiO3lVTE2VTx?= MnvJTWM2OD1yLkCzOkDPxE1? MmfUNlE1PDh3OUG=
SMS-KAN M{e0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX21UHIzOTBizszN MnjPPVYhcA>? NYXqUYs2TE2VTx?= NWjONZlbUUN3ME2wMlA{PCEQvF2= NFyzcGczOTR2OEW5NS=>
SMS-KANR MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe3PIkyOCEQvF2= NXXrc4NDQTZiaB?= MmnhSG1UVw>? NWrj[FZJUUN3ME2wMlAzPiEQvF2= MlWzNlE1PDh3OUG=
SMS-KCN NXfpcFBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHENVAh|ryP NWDDbXh4QTZiaB?= NVHHS29DTE2VTx?= NIjDRlFKSzVyPUCuNFE6KM7:TR?= NVO4cmpXOjF2NEi1PVE>
SMS-KCNR MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjXNVAh|ryP MmT6PVYhcA>? MmLNSG1UVw>? M{LEVmlEPTB;MD6wNVAh|ryP MXGyNVQ1QDV7MR?=
SMS-LHN NF\FVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXexNEDPxE1? NEHkPZM6PiCq MYnEUXNQ NWmycpRSUUN3ME2wMlA{OiEQvF2= NHTmVmczOTR2OEW5NS=>
SMS-MSN NHS0d|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:wcWwyOCEQvF2= M2H2VFk3KGh? MXTEUXNQ NGr1O21KSzVyPUCuNFIzKM7:TR?= M4q4cVIyPDR6NUmx
SMS-SAN M3\FUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LzUFExKM7:TR?= Mn;2PVYhcA>? NYnmVItGTE2VTx?= NHrEeWVKSzVyPUCuNFIxKM7:TR?= MW[yNVQ1QDV7MR?=
Granta-4 MnvzR5l1d3SxeHnjJGF{e2G7 NHXlS24yOCEQvF2= NX\NV|A5PyCm MkG0TWM2OD1yLkC0NEDPxE1? Mn3mNlEzQTF6Nke=
DB NVPRNnRuS3m2b4TvfIlkKEG|c3H5 NFTI[HUyOCEQvF2= NVnUflBkPyCm MXnJR|UxRTBwMESyJO69VQ>? NVvt[mE{OjF{OUG4Olc>
RL M3[we2N6fG:2b4jpZ{BCe3OjeR?= MUOxNEDPxE1? NUnTUZBQPyCm MVnJR|UxRTBwMEG1JO69VQ>? MoTDNlEzQTF6Nke=
K562 M3PuOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWSwUGpKOTBizszN M17ERVk3KGh? MXzJR|UxRTBwMEi3JO69VQ>? MkLJNlExQTF4M{O=
LAMA-84 NXLjS4d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHMXFEyOCEQvF2= NEfMW3g6PiCq NFzReoJKSzVyPUCuNFU4KM7:TR?= MmToNlExQTF4M{O=
MM15 MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXW0JO69VQ>? MYS3NkBp MlTKSG1UVw>? Mn\DTWM2OD1yLkGzJO69VQ>? NVH1UJB3OjB|OEK4OFQ>
OPM1 M4KzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLJOEDPxE1? MnfKO|IhcA>? MVHEUXNQ MYnJR|UxRTBwMEOg{txO MU[yNFM5Ojh2NB?=
RPM1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXm0JO69VQ>? NGiydIU4OiCq MlztSG1UVw>? NUDiRY5TUUN3ME2xNE4{OiEQvF2= NYTVbnZ1OjB|OEK4OFQ>
INA6 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{H6SVQh|ryP NGnO[Zc4OiCq NVHDUI84TE2VTx?= MmP4TWM2OD1yLkCwNkDPxE1? NGnxdI4zODN6Mki0OC=>
OPM2 M33JfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn65OEDPxE1? MkfpO|IhcA>? MXLEUXNQ MXXJR|UxRTRwM{eg{txO M1m4cVIxOzh{OES0
MM1R MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PBN|Qh|ryP NVLVU3h4PzJiaB?= M4TRdGROW09? NYi2U|MxUUN3ME2xMlY5KM7:TR?= M2jqT|IxOzh{OES0
DOX40 NYXNWlhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;NOVQh|ryP MU[3NkBp M{nXR2ROW09? M4G2OWlEPTB;NT60PEDPxE1? NWfsSIt3OjB|OEK4OFQ>
LR5 M3TZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm0OHF2PCEQvF2= NXe0RnI3PzJiaB?= NWLKdXRqTE2VTx?= M2P5UGlEPTB;Mj61N{DPxE1? NISyUFYzODN6Mki0OC=>
U266 M2nU[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HqR|Qh|ryP NG\rTWg4OiCq MX7EUXNQ NF72NZVKSzVyPUGuOFMh|ryP M2S5NlIxOzh{OES0
RD Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXGxNEDPxE1? NGK2UYs6PiCq MW\JR|UxRTBwMkK4JO69VQ>? MUGyNFExQDN|OB?=
Rh41 NVXxd3p2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\JfIkyOCEQvF2= M4OzTlk3KGh? MY\JR|UxRTBwMEmwJO69VQ>? NFH3SWczODFyOEOzPC=>
Rh30 MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGqwVVYyOCEQvF2= NHPV[po6PiCq MoTzTWM2OD1yLkKzNEDPxE1? MWiyNFExQDN|OB?=
BT-12 M3PNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPTPJIyOCEQvF2= Mle0PVYhcA>? NIrVe5pKSzVyPUCuNFYxKM7:TR?= NUjLc|FSOjBzMEizN|g>
CHLA-266 NE\sb4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfUdGgyOCEQvF2= MkX5PVYhcA>? NIT6TZlKSzVyPUCuNFczKM7:TR?= NXfxNnRpOjBzMEizN|g>
TC-71 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlr3NVAh|ryP NV\INXZzQTZiaB?= NVjp[|h1UUN3ME2wMlExOiEQvF2= M3\ucFIxOTB6M{O4
SJ-GBM2 NXrTSZZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n5ZlExKM7:TR?= M3v0V|k3KGh? MkHrTWM2OD1yLkC1NEDPxE1? MXOyNFExQDN|OB?=
NALM-6 NGrQWpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvoNVAh|ryP MnL3PVYhcA>? NIL0cZFKSzVyPUCuNFYzKM7:TR?= MmPNNlAyODh|M{i=
COG-LL-317 M174SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDXOG4yOCEQvF2= MXS5OkBp MmP4TWM2OD1yLkC0O{DPxE1? NFj5WFkzODFyOEOzPC=>
RS4-11 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2L1fVExKM7:TR?= MkXOPVYhcA>? NUPyeldSUUN3ME2wMlAyQCEQvF2= Mk[0NlAyODh|M{i=
MOLT-4 MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmD4NVAh|ryP MlHpPVYhcA>? NH\s[WVKSzVyPUCuNFI3KM7:TR?= MoLxNlAyODh|M{i=
CCRF-CEM Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYT6b|ZsOTBizszN NIHPSHQ6PiCq MmrPTWM2OD1yLkC5OEDPxE1? MlvSNlAyODh|M{i=
Kasumi-1 M{fVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV2xNEDPxE1? Mki4PVYhcA>? NGG4XolKSzVyPUCuNVA{KM7:TR?= M{m5UlIxOTB6M{O4
Karpas-299 NIfvdI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjBfYhCOTBizszN NYCzNWdbQTZiaB?= NWLxbYhVUUN3ME2wMlA{QCEQvF2= NFewOJkzODFyOEOzPC=>
Ramos-RA1 M3PHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjHPI8yOCEQvF2= M2L6eVk3KGh? MVrJR|UxRTBwMUK3JO69VQ>? NEDaXZYzODFyOEOzPC=>

... Click to View More Cell Line Experimental Data

In vivo MLN8237 significantly reduces the tumor burden with tumor growth inhibition (TGI) of 42% and 80% at 15 mg/kg and 30 mg/kg, respectively, and prolongs the survival of mice compared with the control. [2]

Protocol

Kinase Assay:[1]
+ Expand

Aurora A radioactive Flashplate enzyme assay:

Aurora A radioactive Flashplate enzyme assay is conducted to determine the nature and degree of MLN8237-mediated inhibition in vitro. Recombinant Aurora A is expressed in Sf9 cells and purified with GST affinity chromatography. The peptide substrate for Aurora A is conjugated with biotin (Biotin-GLRRASLG). Aurora A kinase (5 nM) is assayed in 50 mM Hepes (pH 7.5), 10 mM MgCl2, 5 mM DTT, 0.05% Tween 20, 2 μM peptide substrate, 3.3 μCi/mL [γ-33P]ATP at 2 μM, and increasing concentrations of MLN8237 by using Image FlashPlates.
Cell Research:[2]
+ Expand
  • Cell lines: MM1.S, MM.1R, LR5, RPMI 8226, DOX40, OPM1, OPM2, INA6, and U266
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are exposed to various concentrations of MLN8237 for 24, 48, and 72 hours. Cells viability is measured using MTT assay, and cell proliferation is measured using 3[H]-thymidine incorporation. For cell cycle analysis, cells are permeabilized by 70% ethanol at -20 °C, and incubated with 50 μg/mL PI and 20 units/mL RNase-A. DNA content is analyzed by flow cytometry using BDFACS-Canto II and FlowJo software. For the detection of apoptosis and senescence, cells are stained with fluorescein isothiocyanate-annexin V and PI. Apoptotic cells are determined by flow cytometric analysis using BDFACS-Canto II and FlowJo software.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immune-deficient (SCID) mice inoculated subcutaneously with MM1.S cells
  • Formulation: Formulated in 10% 2-hydroxypropyl-β-cyclodextrin/1% sodium bicarbonate
  • Dosages: ~30 mg/kg/day
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 27 mg/mL (52.03 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+30% PEG300+5%Tween-80+ddH2O
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 518.92
Formula

C27H20ClFN4O4

CAS No. 1028486-01-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01924260 Active not recruiting Acinar Cell Adenocarcinoma of the Pancreas|Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor Protocol Specific University of California Davis|National Cancer Institute (NCI)|Takeda August 9 2013 Phase 1
NCT01397825 Completed Diffuse Large B-Cell Lymphoma|Transformed Follicular Lymphoma|Mantle Cell Lymphoma|Burkitt''s Lymphoma Millennium Pharmaceuticals Inc.|Takeda August 9 2011 Phase 1|Phase 2
NCT01677559 Completed Adenocarcinoma|Pancreatic Neoplasms Washington University School of Medicine May 7 2013 Phase 1
NCT00697346 Completed B-cell Follicular Lymphoma|B-cell Marginal Zone Lymphoma|Diffuse Large B-cell Lymphoma|B-cell Mantle Cell Lymphoma|B-cell Small Lymphocytic Lymphoma (SLL)|B-Cell Chronic Lymphocytic Leukemia (B-CLL)|Multiple Myeloma|Waldenstrom''s Macroglobulinemia|Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified (PTCL-NOS)|Angioimmunoblastic T-cell Lymphoma (AITL)|Anaplastic Large Cell Lymphoma|Enteropathy Associated T-cell Lymphoma (EATCL)|NK Lymphoma (NKL) Millennium Pharmaceuticals Inc.|Takeda October 7 2008 Phase 1
NCT02860000 Recruiting Estrogen Receptor Status|HER2/Neu Negative|Invasive Breast Carcinoma|Postmenopausal|Stage III Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) July 6 2017 Phase 2
NCT02219789 Completed Estrogen Receptor Positive|Progesterone Receptor Positive|Recurrent Breast Carcinoma|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer Mayo Clinic|National Cancer Institute (NCI) December 5 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the suggested formulation of this compound for mouse injection(i.p.)?

  • Answer:

    It can be dissolved in 6% DMSO/50% PEG 300/5% Tween 80/ddH2O at 10 mg/ml as a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products5

Tags: buy Alisertib (MLN8237) | Alisertib (MLN8237) supplier | purchase Alisertib (MLN8237) | Alisertib (MLN8237) cost | Alisertib (MLN8237) manufacturer | order Alisertib (MLN8237) | Alisertib (MLN8237) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID